2022
DOI: 10.1002/jcla.24332
|View full text |Cite
|
Sign up to set email alerts
|

Abstract: Background Although the phosphorylation of 4E‐BP1 that has been detected in high‐grade prostate cancer has been reported in previous studies, overexpression of p4E‐BP1 and 4EBP1 and their clinical significance in prostate cancer still remain unknown. Methods One hundred six samples of prostate tissues were collected and analyzed by immunohistochemistry with p4E‐BP1 or 4E‐BP1 specific antibodies. Everolimus was used to block the phosphorylation of p4E‐BP1, and then flow cytometry, clone formation, transwell, an… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

0
0
0

Year Published

2022
2022
2023
2023

Publication Types

Select...
2

Relationship

1
1

Authors

Journals

citations
Cited by 2 publications
references
References 17 publications
0
0
0
Order By: Relevance